Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANX008 in Advanced or Metastatic Solid Tumors
NCT05783622Phase 1Active, not recruiting
- Sponsor
- Janux Therapeutics
- Start
- Apr 2023
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of JANX008 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), squamous cell carcinoma of the head and neck (HNSCC) and 4 more (3 arms), sponsored by Janux Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities at 21 days, Incidence of Adverse Events and Serious Adverse Events up to 4 years and 1 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
JANX008
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)squamous cell carcinoma of the head and neck (HNSCC)colorectal carcinoma (CRC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05783622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783622.